A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

NCT00001573 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Glioma
Sarcoma

Interventions

DRUG: SU101

Sponsor

National Cancer Institute (NCI)